GLIDE

Withdrawn

A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia

Glycaemic Control and Management in Adult Type 2 Diabetes Patients Previously Treated With Premix Insulins and Initiating Treatment With IDegLira in Routine Clinical Practice in Croatia: A 36-week Single Arm, Prospective, Multi-centre, Non-interventional Study

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

—

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•HbA1c, change

Identifiers

Registered as

NCT IDNCT05479591

Org study IDNN9068-4972

Secondary IDU1111-1271-8967World Health Organization (WHO)

Timeline

Milestones

Study first posted2022-07-29actual

Study start2022-07-30estimated

Last update posted2022-11-01actual

Primary completion2023-04-30estimated

Study completion2023-04-30estimated

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Participants with Type 2 Diabetes.

Inclusion criteria

•Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

•Male or female patients aged greater than or equal to (>=) 18 years at the time of signing informed consent.

•Patients diagnosed with T2D and receiving treatment with premix insulin for at least 12 weeks (3 months) based on local clinical guidelines.

•Switched to treatment with IDegLira from previous treatment of premix insulins. The decision to initiate treatment with IDegLira must be independently from the decision to enrol in the study.

•Available and documented HbA1c collected within 12 weeks prior to initiation of IDegLira.

Exclusion criteria

•Previous participation in this study. Participation is defined as having given informed consent in this study.

•Participation in any other T2D clinical trial of an approved or non-approved investigational medicinal product within 30 days prior to initiation of IDegLira.

•Previous treatment with IDegLira.

•Patients diagnosed with Type 1 diabetes mellitus.

•Female who is known to be pregnant, breastfeeding or intends to become pregnant during the conduct of the study.

•Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

•Known or suspected hypersensitivity to the active substance or to any of the excipients as specified in the IDegLira label in Croatia.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Other (unclassified)

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Change in body weight

Time frame:From baseline to end of study (week 36 ± 6 weeks)

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint

Change in Glycated Haemoglobin A1c (HbA1c)

Time frame:From baseline to end of study (week 36 ± 6 weeks)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Number of participants with HbA1c less than (<) 7.0%

Time frame:At end of study (week 36 ± 6 weeks)

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Other (unclassified)

2 endpoints

Secondary/protocol endpoint/low confidence

Starting dose of IDegLira

Time frame:At baseline

descriptive

Secondary/protocol endpoint/low confidence

Dose of IDegLira at end of study

Time frame:At end of study (week 36 ± 6 weeks)

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.